Abdominal pain after endoscopic intervention

published_or_final_versio

Cancer risk in patients with diabetic nephropathy: a retrospective cohort study in Hong Kong

published_or_final_versio

Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers

published_or_final_versio

Anti-metastatic mechanism of Tian-Xian Liquid (TXL) and its bioactive fractions in human colorectal cancer cells and xenograft models

Poster Session A: abstract no. 29Colorectal carcinoma is the second most prevalent cancer with an up-rising trend in Hong Kong (Hong Kong Cancer Registry). Traditional Chinese medicine acts as a complementary alternative for tumour therapy with minimal side-effects and traumatic injuries. Tian-Xian Liquid (TXL), one of the well-known natural medicinal herbal formulations, has been commercially used as an anticancer dietary supplement for a decade without known adverse effects. This study aimed to investigate the anti-metastatic property of TXL and its bioactive fractions [butanol fraction (BU), ethyl-acetate fraction (EA) and aqueous fraction (WA)] at molecular level on human colorectal cancer in vitro (HT-29 cancer cells) and in vivo (nude mice xenografts). For the cell model, TXL and its bioactive fractions have similar anti-proliferative effects by MTT assay. At 4-hour-incubation, IC50 values were obtained at 1% (V/V) TXL, 1.25% (V/V) BU, 5% (V/V) EA and 0.3125% (V/V) WA. At IC50, TXL and its bioactive fractions significantly reduced the MMP2 and MMP7 expressions at mRNA level by real-time PCR. At protein level, TXL, BU and EA correspondingly down-regulated MMP2 (active form) and MMP7 protein from 24 to 48 hours; TXL and BU also down-regulated VEGF protein expression; however, no such effect was found in WA-treated cells. Further, only TXL, EA and WA effectively inhibited the cell migration at 48 hours incubation by woundhealing assay. For the xenografts models, MMP2 and MMP7 mRNA expressions were reduced by TXL-, BU- and EA-treated xenografts; however no effects on MMP2 protein expression in all drug-treated xenografts. The VEGF protein expression was significantly down-regulated in TXL- and WA-treated xenografts. Further, TXL, BU and WA effectively inhibited the tumor growth without altering the body weight of the xenografts. In summary, the Chinese medicinal formulation, TXL, demonstrated the most effective anti-metastatic ability on human colorectal cancer in vitro and in vivo.published_or_final_versio

Serum adiponectin levels are predictive of carotid intima-medial thickness in a 5-year community-based prospective study

Poster PresentationINTRODUCTION: Hypoadiponectinaemia has been shown to predict the development of type 2 diabetes, hypertension, and myocardial infarction in prospective studies. We have previously reported that hypoadiponectinaemia is associated with impaired endothelium-dependent vasodilation both in healthy controls and diabetic subjects. In this community-based prospective cohort study, we examined the predictive value of serum adiponectin levels on carotid intima-medial thickness, a marker of …published_or_final_versionThe 17th Medical Research Conference, The University of Hong Kong, Hong Kong, 14 January 2012. In Hong Kong Medical Journal, 2012, v. 18 suppl. 1, p. 32, abstract no. 4

Suppression of nickel release in nickeltitanium alloys by plasma immersion ion implantation surface treatment: towards a new generation of "smart" orthopaedic implants

Summary form only given. Nickel-titanium shape memory alloys (NiTi) are potentially very useful in spinal deformity correction due to their super elastic properties and their ability to change shape with temperature. However, release of toxic nickel particulate debris remains a major concern. We have developed a novel method of altering the surface of the material to reduce nickel release by using plasma immersion ion implantation (PIII). This study compares the corrosion resistance and mechanical properties of PIII treated samples with untreated NiTi. NiTi discs containing 50.8% Ni were implanted with nitrogen using PIII technique. Their elemental depth profile, surface chemical composition, surface hardness and corrosion resistance were compared with untreated NiTi. The amount of Ni released into simulated body fluids after the accelerated corrosion tests were determined. The biocompatibility was assessed by culturing mouse osteoblasts expressing an enhanced green fluorescent protein on the surface of these materials. After PIII treatment, a layer of titanium nitride formed on the surface. Compared to untreated NiTi, the corrosion resistance is better by five times, and the surface hardness and elastic modulus are better by a factor of 2. The concentration of Ni in the simulated body fluid for the untreated sample was 30 ppm compared to undetectable levels in the PIII treated sample. There was no difference in the ability of cells to grow on either surface. PIII results in enhanced corrosion and wear resistance, and negligible Ni release. This technique will allow NiTi alloys to be safely implanted in the human body. A new generation of "smart" orthopaedic implants will likely result.published_or_final_versio

Ketamine-induced cholangiopathy: A case report

postprin

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.

In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

The incidence and prevalence of heart failure (HF) and chronic kidney disease (CKD) are increasing, and as such a better understanding of the interface between both conditions is imperative for developing optimal strategies for their detection, prevention, diagnosis, and management. To this end, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international, multidisciplinary Controversies Conference titled Heart Failure in CKD. Breakout group discussions included (i) HF with preserved ejection fraction (HFpEF) and nondialysis CKD, (ii) HF with reduced ejection fraction (HFrEF) and nondialysis CKD, (iii) HFpEF and dialysis-dependent CKD, (iv) HFrEF and dialysis-dependent CKD, and (v) HF in kidney transplant patients. The questions that formed the basis of discussions are available on the KDIGO website http://kdigo.org/conferences/heart-failure-in-ckd/, and the deliberations from the conference are summarized her